Table 6.
Multivariate Cox regression model to predict the risk of the development of adverse outcomes (progression and death) in patients with COVID-19.
| Variable | Hazard ratio | 95% Confidence interval | P | |
|---|---|---|---|---|
| Severe COVID-19 | 4.18x104 | 1.34x104-1.31x105 | <0.0001 | |
| Critical COVID-19 | 5.35x105 | 1.71x105-1.67x106 | <0.0001 | |
| Body mass index | 1.17 | 1.02-1.07 | 0.001 | |
| Neutrophil/lymphocyte ratio | 1.05 | 1.02-1.07 | <0.0001 | |
| Troponin I (pg/mL) | 1.002 | 1.001-1.003 | 0.002 | |
| Lactate deshydrogenase (AU) | 1.003 | 1.00-1.005 | 0.024 | |
| IP-10 (pg/mL) | 1.00 | 1.00-1.001 | 0.001 | |
| 3,4 dihydroxybutanoic acid (AU) | 1.45 | 1.18-1.78 | <0.0001 | |
| Malic acid (AU) | 1.45 | 1.22-1.73 | <0.0001 | |
| Citric acid (AU) | 0.73 | 0.59-0.99 | 0.003 | |
| Myoinositol (AU) | 0.97 | 0.95-0.99 | 0.008 | |
| Cystine (AU) | 1.13 | 1.06-1.20 | <0.0001 | |